NewsRoom Articles - Page 677 of 791

TuesdayMar 14, 2017 11:00 am

Akari Therapeutics Plc (NASDAQ: AKTX) Starts Presentation at 29th Annual ROTH Conference

Akari Therapeutics (NASDAQ: AKTX) is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. The company is currently conducting a phase Ib clinical trial of Coversin. For more information, visit the company’s website at www.akaritx.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press…

TuesdayMar 14, 2017 11:00 am

Spartan Motors, Inc. (NASDAQ: SPAR) Starts Presentation at 29th Annual Roth Conference

Spartan Motors (NASDAQ: SPAR) engineers, manufactures and sells heavy-duty and custom vehicles in the United States, Canada, South America and Asia. The Emergency Response Vehicles segment offers emergency response chassis and bodies, and aerial ladder components. The Delivery and Service Vehicles segment provides walk-in vans for use in the package delivery, one-way truck rental, bakery/snack delivery, utility and linen/uniform rental businesses; and commercial truck bodies, as well as interior equipment up fitting and aftermarket parts. The Specialty Chassis and Vehicles segment offers motor home chassis, defense vehicles, and other specialty chassis, as well as distributes related aftermarket parts and assemblies.…

TuesdayMar 14, 2017 11:00 am

BIOLASE, Inc. (NASDAQ: BIOL) Starts Presentation at 29th Annual ROTH Conference

BIOLASE (NASDAQ: BIOL) is a medical device company that develops, manufactures and markets laser systems in dentistry and medicine in the United States and internationally. It offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used in soft tissue, pain therapy, and cosmetic procedures, such as teeth whitening. The company’s dental laser systems allow dentists, periodontists, endodontists, oral surgeons and other dental specialists to perform a range of dental procedures, including cosmetic, restorative, and complex surgical applications. For more information, visit the company’s website at www.biolase.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation…

TuesdayMar 14, 2017 10:41 am

India Globalization Capital, Inc. (NYSE: IGC) is “One to Watch”

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions. The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC’s patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its…

TuesdayMar 14, 2017 10:30 am

Reis, Inc. (NASDAQ: REIS) Starts Presentation at 29th Annual Roth Conference

Reis (NASDAQ: REIS) provides commercial real estate market information and analytical tools to real estate professionals in the United States. It maintains a proprietary database containing information on commercial properties, including apartment, office, retail, warehouse/distribution, flex/research and development, self-storage plus senior and student housing properties in metropolitan markets and neighborhoods. The company’s data is used by real estate investors, lenders, and other professionals to make informed buying, selling, and financing decisions, plus debt and equity investors to assess, quantify, and manage the risks of default and loss associated with individual mortgages, properties, portfolios and real estate backed securities. For more…

TuesdayMar 14, 2017 10:30 am

Broadwind Energy, Inc. (NASDAQ: BWEN) Starts Presentation at 29th Annual ROTH Conference

Broadwind Energy (NASDAQ: BWEN) provides components and gearing as well as other specialized applications for customers in the clean tech, energy and infrastructure markets. The company is a precision manufacturer of these structures, equipment and components. With facilities throughout the U.S., the company is committed to helping customers maximize performance of their investments in a quicker, easier and smarter way. For more information, visit the company’s website at www.bwen.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an…

TuesdayMar 14, 2017 10:30 am

Neogen Corp. (NASDAQ: NEOG) Starts Presentation at 29th Annual Roth Conference

Neogen (NASDAQ: NEOG) develops, manufactures and markets various products and services for food and animal safety worldwide. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed. The Animal Safety segment provides pharmaceuticals, rodenticides, disinfectants, vaccines, veterinary instruments, topicals, diagnostic products, and genetic testing services to the animal safety market. Its products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi and viruses. For more information, visit the company’s website at www.neogen.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication,…

TuesdayMar 14, 2017 10:30 am

Vascular Biogenics Ltd. (NASDAQ: VBLT) Starts Presentation at 29th Annual Roth Conference

Vascular Biogenics (NASDAQ: VBLT), operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” phase 1 trial as well as in three tumor-specific phase 2 studies. Ofranergene obadenovec…

TuesdayMar 14, 2017 10:30 am

Insperity, Inc. (NYSE: NSP) Starts Presentation at 29th Annual ROTH Conference

Insperity (NYSE: NSP) provides an array of human resources and business solutions designed to help improve business performance. Insperity® Business Performance Advisors offers a comprehensive suite of products and services. The company delivers administrative relief, better benefits, reduced liabilities and a systematic way to improve productivity through its premier Workforce Optimization® solution. Additional company offerings include human capital management, payroll software, time and attendance, performance management, organizational planning, recruiting services, employment screening, financial services, expense management, retirement services and insurance services. For more information, visit the company’s website at www.insperity.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release…

TuesdayMar 14, 2017 10:30 am

vTv Therapeutics, Inc. (NASDAQ: VTVT) Starts Presentation at 29th Annual Roth Conference

vTv Therapeutics (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company that discovers, develops and sells orally administered small molecule drug candidates worldwide. The company’s drug candidate for the treatment of Alzheimer’s disease comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation end-products, which is in Phase III clinical trials. Its Type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in phase II clinical trials. For more information, visit…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Akari Therapeutics Plc (NASDAQ: AKTX) Starts Presentation at 29th Annual ROTH Conference

Spartan Motors, Inc. (NASDAQ: SPAR) Starts Presentation at 29th Annual Roth Conference

BIOLASE, Inc. (NASDAQ: BIOL) Starts Presentation at 29th Annual ROTH Conference

India Globalization Capital, Inc. (NYSE: IGC) is “One to Watch”

Reis, Inc. (NASDAQ: REIS) Starts Presentation at 29th Annual Roth Conference

Broadwind Energy, Inc. (NASDAQ: BWEN) Starts Presentation at 29th Annual ROTH Conference

Neogen Corp. (NASDAQ: NEOG) Starts Presentation at 29th Annual Roth Conference

Vascular Biogenics Ltd. (NASDAQ: VBLT) Starts Presentation at 29th Annual Roth Conference

Insperity, Inc. (NYSE: NSP) Starts Presentation at 29th Annual ROTH Conference

vTv Therapeutics, Inc. (NASDAQ: VTVT) Starts Presentation at 29th Annual Roth Conference

NetworkNewsWire Currently Accepts

NetworkNewsWire

Financial news and publishing for public and private companies

Contact us: 212.418.1217

NetworkNewsWire Currently Accepts

Company Search

Site Search